TREATMENT OPTIONS Randomised controlled trials

• Few RCTs, few patients/study (error type II)

• Few RCTs including children

• Heterogeneity (inclusions criteria and end-points)

• Different lengths of follow-up

• 2 Meta-analysis: prophylaxis, chronic LD

• USA/Europe: prophylaxis: USA ECM: 9 Europe/5USA arthritis: >> USA neuroborreliosis: >> Europe

Previous slide

Next slide

Back to first slide

View graphic version